<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137993">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02071381</url>
  </required_header>
  <id_info>
    <org_study_id>DW340-1001</org_study_id>
    <nct_id>NCT02071381</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of DDI Between DW330SR and DW1030 in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Open Label, Single-Dose, 6-sequence, 3-period, Crossover Study to Evaluate a Pharmacokinetic Drug Interaction Between DW330SR and DW1030 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewon Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewon Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate drugs interactions to compare pharmacokinetics in
      groups of monotherapy DW330SR, monotherapy DW1030, and coadministration DW330SR and DW1030
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Trans-OH as Main Metabolites of DW330SR, DW330SR, Cmax, AUClast of DW1030</measure>
    <time_frame>-28 ~ -2day(screening), -1day, 1day, 2day</time_frame>
  </primary_outcome>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>only DW330SR 45mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>only DW1030 75mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DW330SR 45mg and DW1030 75mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW330SR 45mg</intervention_name>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DW1030 75mg</intervention_name>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Adult males aged 20~40 years at screening visit

          -  Subjects with range of 19 kg/m2 ~ 27 kg/m2 as BMI measurements at screening visit

          -  Subjects with BP range of below:

             90 mmHg ≤ Systolic BP ≤ 140 mmHg 50 mmHg ≤ Diastolic BP ≤ 90mmHg

          -  Subjects who voluntarily agreed with written consent that be able to understand the
             objective, method of the study, the characteristics of investigational drug, and
             comply with the reguirement of the study

        Exclusion Criteria:

          -  Subjects with clinically significant disease or history  such as Liver, kidney,
             gastrointestinal, respiratory, musculoskeletal, endocrine, nervous psychiatric, blood
             tumor system and cardiovascular. (In particular, bronchial asthma, severe hepatic,
             renal failure, severe blood disorders, severe myasthenia gravis, cardiac dysfunction,
             peptic ulcer, etc.)

          -  Subjects with history of gastrointestinal disease (ex, Chrones dz, peptic ulcer, etc)
             affect the absorption of Investigational drugs or history of surgery (except for a
             simple appendectomy or hernia surgery)

          -  Subjects with hypersensitivity reaction or clinically significant disease in drugs
             (Aspirin, NSAID and antibiotics) including ingredient of DW330SR and DW1030 and Food
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Asan Medical Center IRB</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gyu-Jeong Noh, M.D, Ph.D</last_name>
      <phone>+82-2-3010-4612</phone>
      <email>nohgj@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Gyu-Jeong Noh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 23, 2014</lastchanged_date>
  <firstreceived_date>February 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
